https://orcid.org/0000-0002-4658-7391
Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Sara Cacciapuoti, Matteo Megna, Emanuela Salza, Luca Potestio & Giuseppina Caiazzo. (2024) The effect of tildrakizumab on adipokines production in patients affected by psoriasis and obesity: preliminary results from a single center real-life study. Journal of Dermatological Treatment 35:1.
Read now
Read now
Angelo Ruggiero, Antonio Portarapillo, Matteo Megna, Cataldo Patruno & Maddalena Napolitano. (2023) Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics. Pediatric Health, Medicine and Therapeutics 14, pages 435-451.
Read now
Read now
Luca Potestio, Elisa Camela, Sara Cacciapuoti, Luigi Fornaro, Angelo Ruggiero, Fabrizio Martora, Teresa Battista & Matteo Megna. (2023) Biologics for the Management of Erythrodermic Psoriasis: An Updated Review. Clinical, Cosmetic and Investigational Dermatology 16, pages 2045-2059.
Read now
Read now
Matteo Megna, Elisa Camela, Angelo Ruggiero, Teresa Battista, Fabrizio Martora, Sara Cacciapuoti & Luca Potestio. (2023) Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?. Clinical, Cosmetic and Investigational Dermatology 16, pages 1677-1690.
Read now
Read now
Luca Potestio, Elisa Camela, Sara Cacciapuoti, Fabrizio Martora, Luigi Guerriero, Luigi Fornaro, Angelo Ruggiero & Matteo Megna. (2023) Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation. Expert Opinion on Drug Safety 22:11, pages 1003-1010.
Read now
Read now
Angelo Ruggiero, Luca Potestio, Fabrizio Martora, Alessia Villani, Rosita Comune & Matteo Megna. (2023) Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert Opinion on Drug Safety 22:5, pages 355-362.
Read now
Read now
Articles from other publishers (1)
Sonsoles Berenguer‐Ruiz, Mario Aparicio‐Domínguez, Pedro Herranz‐Pinto, Ricardo Ruíz‐Villaverde, Anna López‐Ferrer, Jorge Santos‐Juanes, Lourdes Rodríguez Fernández‐Freire, Mercedes Hospital‐Gil, Salvador Arias‐Santiago, Gregorio Carretero‐Hernández, Almudena Mateu‐Puchades, Marta Ferran, Elena del Alcázar, Sergio Santos‐Alarcón, Francisco Javier Garcia‐Latasa de Aranibar, Isabel Belinchón‐Romero, Álvaro González‐Cantero, Diana Ruíz‐Genao, Noemí Eiris‐Salvado, Vicenç Rocamora‐Durán, Raquel Rivera‐Diaz, Pablo de la Cueva, Esteban Daudén, Laura Salgado‐Boquete & Mar Llamas‐Velasco. (2023) Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Journal of the European Academy of Dermatology and Venereology 37:12, pages 2517-2525.
Crossref
Crossref